Alvotech

Based in Luxembourg, Alvotech develops and manufactures biosimilar medicines targeting autoimmune, ophthalmologic, oncologic, and bone disorders. The company's portfolio includes AVT02, a high-concentration formulation biosimilar to Humira for inflammatory conditions such as rheumatoid arthritis and Crohn's disease; AVT04, a biosimilar to Stelara for psoriatic arthritis and ulcerative colitis; AVT06, a biosimilar to Eylea for age-related macular degeneration and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia for cancer-related bone complications and osteoporosis prevention. The company also develops AVT05 (Simponi biosimilar), AVT16 (Entyvio biosimilar), AVT23 (Xolair biosimilar), and AVT33 (Keytruda biosimilar in early-stage development).

Alvotech operates across multiple therapeutic areas within the biosimilar space, with products in various stages of development and commercialization. The company's revenue streams derive from the development and commercialization of its biosimilar candidates, though specific segment breakdowns are not publicly disclosed. The organization employs approximately 1,012 full-time employees and operates on a global scale, bringing biosimilar alternatives to market across numerous indications where the company addresses opportunities created by expiring patent protections on reference biologics.